 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses CD73/PD-1 DFC demonstrated superior...

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the...

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first timeSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company...

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...

Cidara Therapeutics Named as a San Diego Metro Area Top Workplace

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cidara Therapeutics management to meet with Needham

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Free Report)  Research analysts at HC Wainwright boosted their FY2023 earnings per share estimates for shares of Cidara Therapeutics in a...

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Expected to Earn FY2023 Earnings of ($0.28) Per Share

Cidara Therapeutics (NASDAQ:CDTX  Get Free Report) was downgraded by analysts at StockNews.com from a buy rating to a hold rating in a research note issued to...

Cidara Therapeutics (NASDAQ:CDTX) Stock Rating Lowered by StockNews.com

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC...

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38  Annual Meeting

Legacy Wealth Asset Management LLC bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX  Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 30,000...

30,000 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by Legacy Wealth Asset Management LLC

Revenue Totals $12.7 Million, Cash and Cash Equivalents Reach $48.7 MillionRelated Stocks: CDTX...

Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Market Cap	$67.03M
Volume (M)	11,455.00
52-Wk High	$2.10
52-Wk Low	$0.465

CDTX Cidara Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community